发明申请
US20150110793A1 Humanized Anti-Epiregulin Antibody, and Cancer Therapeutic Agent Comprising Said Antibody as Active Ingredient
有权
人源化抗前列腺素抗体和包含所述抗体作为活性成分的癌症治疗剂
- 专利标题： Humanized Anti-Epiregulin Antibody, and Cancer Therapeutic Agent Comprising Said Antibody as Active Ingredient
- 专利标题（中）： 人源化抗前列腺素抗体和包含所述抗体作为活性成分的癌症治疗剂
-
申请号： US14369539申请日： 2012-12-28
-
公开(公告)号： US20150110793A1公开(公告)日： 2015-04-23
- 发明人: Hirotake Shiraiwa , Keiko Esaki , Tomoyuki Igawa , Taichi Kuramochi , Atsuhiko Maeda , Shigero Tamba , Hiroyuki Tsunoda , Tatsuhiko Tachibana , Yasuko Kinoshita , Masami Suzuki , Atsuhiko Kato , Etsuko Takeiri , Eri Hashimoto , Yoshinori Watanabe
- 申请人： Chugai Seiyaku Kabushiki Kaisha
- 优先权： JP2011-287654 20111228; JP2012-133394 20120613
- 国际申请： PCT/JP2012/084042 WO 20121228
- 主分类号： C07K16/22
- IPC分类号： C07K16/22
摘要：
The inventors successfully produced anti-Epiregulin antibodies showing cross-species reactivity between cynomolgus monkey (non-human animals) and human, anti-Epiregulin antibodies with suppressed chemical degradation, anti-Epiregulin antibodies with lowered isoelectric point, anti-Epiregulin antibodies with increased thermal denaturation midpoint temperature, and anti-Epiregulin antibodies with reduced amount of aggregate by performing appropriate amino acid residue substitutions in the variable-region sequences of the humanized EP27 antibody which inhibits growth of cancer cells by exhibiting cytotoxic activity and neutralizing activity against human Epiregulin-expressing cancer cells.
公开/授权文献
信息查询
